GlaxoSmithKline, SK Bioscience Start Final Trial Of COVID-19 Jab.

GlaxoSmithKline, SK Bioscience Start Final Trial Of COVID-19 Jab

General view outside GlaxoSmithKline (GSK) headquarters in Brentford (Reuters)

London:

British drugs giant GlaxoSmithKline and South Korean peer SK bioscience have begun final stage trials of a Covid-19 jab after positive early results, they announced Tuesday.

The vaccine is facing a Phase 3 clinical trial to assess its "safety and immunogenicity" when compared with AstraZeneca's Covid vaccine, the two companies said in a joint statement.

GSK is still trailing in the wake of Anglo-Swedish rival AstraZeneca, which rapidly developed a successful jab alongside Oxford University despite having little prior experience in vaccine development.

The new jab combines SK bioscience's Covid vaccine candidate GBP510 with Glaxo's pandemic adjuvant that bolsters the immune response.

"The advance to Phase 3 study follows positive interim Phase 1/2 data which showed that all participants who received the adjuvanted vaccine candidate developed strong neutralising antibody responses," the pair said Tuesday.

Those responses demonstrated a rate of seroconversion -- or production of antibodies -- of 100 percent, they added.

No safety concerns have so far been identified in the study.

The vaccine is then expected to be supplied via COVAX -- the distributor backed by the World Health Organization and the Gavi vaccine alliance -- subject to positive results and regulatory approvals.

"While many countries have made good progress with vaccination, there remains a need for accessible and affordable COVID-19 vaccines to ensure equitable access and to protect people across the world," said GSK chief global health officer Thomas Breuer.

"We are pleased to contribute with GSK's pandemic adjuvant and to be working with SK to deliver the vaccine at scale via COVAX if it is approved."

Results from the Phase 3 trial, which will enrol 4,000 participants from various nations, are expected in the first half of next year.

This will be the first Phase 3 study to compare outcomes of two different Covid-19 vaccine candidates.

SK has received funding from the Coalition for Epidemic Preparedness Initiative and the Bill & Melinda Gates Foundation to help it develop a low-cost jab.

"Taking this important step towards overcoming the global pandemic situation, SK and GSK will bring our technical expertise together for the development of an adjuvanted protein-based vaccine candidate, GBP510," noted SK chief executive Jaeyong Ahn.

Glaxo is also working with French pharmaceutical giant Sanofi on final Phase 3 tests of a different Covid vaccine, which they hope to launch by the end of this year.

Phase 2 trials of that jab have already showed a strong immune response after a single shot in participants who had previously contracted the coronavirus.

GSK is also working on another two separate vaccine projects, one with Canada's Medicago and another with Germany's CureVac.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news

Saudi Arabia Aims For Zero Carbon Emissions By 2060.

Saudi Arabia's crown prince said on Saturday that the world's top oil exporter aims to reach zero-net emissions by 2060 and more than double its annual target to reduce carbon emissions.

NDTV News

LIVE: Rep. Kevin McCarthy Holds Weekly Briefing On Capitol Hill - NBC News

LIVE: Rep. Kevin McCarthy Holds Weekly Briefing On Capitol Hill - NBC News

Watch live coverage as Minority Leader Rep. Kevin McCarthy holds his weekly briefing. » Subscribe to NBC News: » Watch more NBC video: NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and eng...

Simone Biles Speaks Out On Championing Mental Health.

Simone Biles Speaks Out On Championing Mental Health.

Olympic gymnastics icon and newly appointed Chief Impact Officer for online mental health platform Cerebral, Simone Biles, joins News NOW along with founder and CEO of Cerebral, Kyle Robertson, to talk about Bile’s decision to withdraw from compet...

House To Vote On Holding Steve Bannon In Contempt Of Jan.

House To Vote On Holding Steve Bannon In Contempt Of Jan.

The House is set to vote on whether to refer former advisor to President Trump, Steve Bannon, to the Justice Department after his refusal to cooperate with the January 6th investigation. NBC News’ Leigh Ann Caldwell breaks down how lawmakers are e...

LIVE: Speaker Pelosi Holds Weekly Briefing On Capitol Hill - NBC News.

LIVE: Speaker Pelosi Holds Weekly Briefing On Capitol Hill - NBC News.

Watch live coverage as House Speaker Nancy Pelosi holds her weekly press conference. » Subscribe to NBC News: » Watch more NBC video: NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and enga...

US surgeon general on child vaccines: Parents have been waiting for this.

US surgeon general on child vaccines: Parents have been waiting for this.

US Surgeon General Dr. Vivek Murthy speaks with CNN's John Berman after the White House unveiled its plans to roll out Covid-19 vaccines for children ages 5 to 11, pending US Food and Drug Administration authorization. #CNN #News

COVID-19: Prime Minister says 'we're in a much better position

COVID-19: Prime Minister says 'we're in a much better position" because of the vaccine.

Boris Johnson, the Prime Minister, says the country "must fortify ourselves further" in the face of rising COVID-19 cases and that those who are offered the vaccine and their booster jabs should come forward. He said the country "needed to keep go...